14-day Premium Trial Subscription Try For FreeTry Free
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of TTNP
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Titan Pharmaceuticals stock price down 0% on Thursday
(Updated on Apr 25, 2024)

Sell candidate since Apr 23, 2024 Loss -0.57% PDF

No changes to the price of Titan Pharmaceuticals stock on the last trading day (Thursday, 25th Apr 2024). During the last trading day the stock fluctuated 0% from a day low at $6.97 to a day high of $6.97. The price has fallen in 4 of the last 10 days and is down by -2.65% for this period.

The stock lies in the lower part of a very wide and weak rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $6.45 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 8.22% during the next 3 months and, with a 90% probability hold a price between $6.98 and $10.41 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

TTNP Signals & Forecast

There are mixed signals in the stock today. The Titan Pharmaceuticals stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $7.07 and $7.22. A break-up above any of these levels will issue buy signals. Volume fell on the last day without any changes to the price. This does not cause any direct divergence but may be an early warning and a possible "turning point". The very low volume increases the risk and reduces the other technical signals issued. A buy signal was issued from a pivot bottom point on Wednesday, April 24, 2024, and so far it has fallen 0%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss for Titan Pharmaceuticals stock

Titan Pharmaceuticals finds support from accumulated volume at $6.83 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

In general the stock tends to have very controlled movements and therefore the general risk is considered very low. However, be aware of low or falling volume and make sure to keep an eye on the stock During the last day, the stock moved $0 between high and low, or 0%. For the last week the stock has had daily average volatility of 1.09%

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (TTNP) For The Upcoming Trading Day Of Friday 26th

For the upcoming trading day on Friday, 26th we expect Titan Pharmaceuticals to open at $6.97, and during the day (based on 14 day Average True Range), to move between $6.58 and $7.36, which gives a possible trading interval of +/-$0.388 (+/-5.57%) up or down from last closing price. If Titan Pharmaceuticals takes out the full calculated possible swing range there will be an estimated 11.14% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $6.83 (2.01%) than the resistance at $7.24 (3.87%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Titan Pharmaceuticals stock A Buy?

Titan Pharmaceuticals holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -2.165 Sell Candidate Unchanged

Predicted Opening Price for Titan Pharmaceuticals of Friday, April 26, 2024

Fair opening price April 26, 2024 Current price
$6.97 ( 0%) $6.97

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for TTNP

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 6.97 .
R2 6.97 .
R1 6.97 .
Current price: 6.97
Support S1 6.97 .
S2 6.97 .
S3 6.97 .

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 7.38 5.88 %
R2 7.26 4.16 %
R1 7.24 3.87 %
Current price 6.97
Support S1 6.83 -2.01%
S2 6.45 -7.46%
S3 6.29 -9.76%

FAQ

What is the symbol for Titan Pharmaceuticals Stock and on which exchange is it traded?
The symbol for Titan Pharmaceuticals is TTNP and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Titan Pharmaceuticals Stock?
Titan Pharmaceuticals holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

How to buy Titan Pharmaceuticals Stock?
Titan Pharmaceuticals Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Titan Pharmaceuticals Stock.

What's the current price of Titan Pharmaceuticals Stock?
As of the end of day on the Apr 25, 2024, the price of an Titan Pharmaceuticals (TTNP) share was $6.97.

What is the 52-week high and low for Titan Pharmaceuticals Stock?
The 52-week high for Titan Pharmaceuticals Stock is $9.29 and the 52-week low is $0.250.

What is the market capitalization of Titan Pharmaceuticals Stock?
As of the Apr 25, 2024, the market capitalization of Titan Pharmaceuticals is 6.372M.

When is the next earnings date for Titan Pharmaceuticals?
The upcoming earnings date for Titan Pharmaceuticals is May 20, 2024.
Click to get the best stock tips daily for free!

About Titan Pharmaceuticals

Titan Pharmaceuticals Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination... TTNP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT